Yukio Suzuki, MD, PhD, on Endometrial Cancer: Long-Term Survival Outcomes With Hormonal Therapy in Reproductive-Age Patients
2024 ASCO Annual Meeting
Yukio Suzuki, MD, PhD, of Columbia University College of Physicians and Surgeons, discusses data showing that reproductive-age patients with early-stage endometrial cancer who use fertility-preserving hormonal therapy seemed to have good overall survival after a 10-year follow-up (Abstract 5508).
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
What we are going to look at is to determine the trends in and use of primary hormonal therapy use, and also long-term survival outcomes for hormonal therapy in premenopausal patient with early stage endometrial cancer. The design of this study is retrospective cohort study, and we use national cancer database which registered around 70% of newly diagnosed cases in the US. We have two major parts in this study and the fourth one is looking at the trends in and patterns of use of primary hormonal therapy in the premenopausal patient with early stage endometrial cancer. And the second one is survival outcome for the patient with early stage endometrial cancer. We included patients 18 to 49 years old and clinical stage 1 endometrial cancer and grade one [inaudible 00:01:01] 2 endometrial cancer. Main finding of our study is the utilization rate of primary hormonal therapy rose from 4% to 5% around 2004 to 2010, and it's going up to 12% to 14% in 2020.
Younger age, non-white race patients who live in metropolitan area, patient who are treated at academic cancer center, patient who are treated at the facilities located at Northeast area in the US were associated with primary hormonal therapy use. In terms of tumor characteristics, grade 1 and stage 1A were associated with primary hormonal therapy use. For survival outcomes, the propensity score match cohort is well-balanced between the two primary treatment group. Overall, after 10 year follow up, the survival rate was decreased by 4.1% in hormonal therapy group compared with hysterectomy group. Hazard ratio was 1.84.
In age subgroup, patient younger than 40 years old, the two primary treatment group of the survival rate was similar at any time point, five year and 10 year point. Surprisingly among age 40 to 49, the survival rate was inferior in hormonal therapy group then hysterectomy group at five year point and 10 year point. Hazard ratio was 4.94.
To conclude, given the growing number of patient with early stage endometrial cancer who may desire fertility preservation, we need to consider potentially poorer prognosis when patients and provider select the primary hormonal therapy use. Shared decision making is further needed for this space and also prospective study with large sample sites should be needed for making this evidence more robust.
The ASCO Post Staff
Katherine C. Fuh, MD, PhD, of the University of California, San Francisco, discusses phase III findings of the AXLerate-OC trial, showing that batiraxcept with paclitaxel compared to paclitaxel alone improved progression-free and overall survival in patients with platinum-resistant recurrent ovarian cancer whose tumors were AXL-high in an exploratory analysis (LBA5515).
The ASCO Post Staff
Allison M. Winter, MD, of the Cleveland Clinic Taussig Cancer Institute, discusses real-world outcomes with lisocabtagene maraleucel in patients with Richter transformation, a difficult-to-treat population with a poor prognosis. Data from the Center for International Blood and Marrow Transplant Research showed this therapy provided clinical benefit with a high complete response rate (Abstract 7010).
The ASCO Post Staff
Peter Riedell, MD, of The University of Chicago, discusses phase III findings on the regimen of brentuximab vedotin in combination with lenalidomide and rituximab for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This therapy demonstrated a survival advantage in the third-line setting, but as this is an interim analysis, questions remain regarding long-term safety and duration of response, according to Dr. Riedell (Abstract LBA7005).
The ASCO Post Staff
David J. Andorsky, MD, of the Sarah Cannon Research Institute and Rocky Mountain Cancer Centers, discusses EPCORE NHL-6, an ongoing study of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). As outpatients, the study participants were given subcutaneous epcoritamab-bysp to see whether they could be safely monitored and cytokine-release syndrome appropriately managed in the outpatient setting (Abstract 7029).
The ASCO Post Staff
Milana Bergamino Sirvén, MD, PhD, of Spain’s Institute of Cancer Research, discusses her findings on molecular profiling of patients with estrogen receptor–positive, HER2-positive early-stage breast tumors after short-term preoperative endocrine therapy. This study suggests that such profiling may help clinicians identify those patients with a favorable prognosis for adjuvant endocrine therapy and those who may require additional treatment (Abstract 560).